Venetoclax Added to Cladribine (CLAD) plus Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study

被引：3

作者：

Reville, Patrick K. ^{[1
]}

Kantarjian, Hagop ^{[2
]}

Borthakur, Gautam ^{[1
]}

Pemmaraju, Naveen ^{[1
]}

Daver, Naval ^{[1
]}

DiNardo, Courtney D. ^{[1
]}

Sasaki, Koji ^{[1
]}

Short, Nicholas ^{[1
]}

Issa, Ghayas C. ^{[1
]}

Ohanian, Maro ^{[1
]}

Jabbour, Elias ^{[1
]}

Montalban-Bravo, Guillermo ^{[1
]}

Maiti, Abhishek ^{[1
]}

Jain, Nitin ^{[3
]}

Ferrajoli, Alessandra ^{[1
]}

Bhalla, Kapil N. ^{[1
]}

Takahashi, Koichi ^{[1
]}

Rausch, Caitlin R. ^{[4
]}

Hammond, Danielle ^{[1
]}

Malla, Rashmi ^{[1
]}

Quagliato, Kelly ^{[1
]}

Brandt, Mark ^{[1
]}

Popat, Uday R. ^{[5
]}

Konopleva, Marina ^{[1
]}

Garcia-Manero, Guillermo ^{[1
]}

Ravandi, Farhad ^{[1
]}

Kadia, Tapan M. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Div Canc Med, Houston, TX 77030 USA

[3] MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[4] MD Anderson Canc Ctr, Pharm, Houston, TX USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-168029

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

616

引用

页码：9041 / 9043

页数：3